Abstract
Young breast cancer patients have a decreased survival rate and it has been demonstrated that young age is an independent predictor of adverse prognosis. Overexpression of c-erbB-2 protein (also known as HER-2/neu) has been shown to be a prognostic indicator in breast cancer in general and especially among patients with axillary nodal metastases. The present study was initiated to determine the prognostic significance of c-erbB-2 protein overexpression in early onset breast cancer.
A population consisting of 110 young breast cancer patients, ≤ 36-year-old at diagnosis, was analyzed with immunohistochemical staining for c-erbB-2 protein.
Thirty patients (27%) were found to overexpress the c-erbB-2 protein. C-erbB-2 positivity was significantly associated with poor survival when all patients were included in the analysis (P = 0.002) and for patients with axillary nodal metastases (P = 0.0007). No such association was found for node-negative patients. Furthermore, the difference in prognosis in relation to c-erbB-2 among node-positive patients was maintained, when these were stratified in groups treated or not treated with adjuvant chemotherapy.
The study indicates that overexpression of c-erbB-2 protein is a strong prognostic factor in young breast cancer patients with axillary nodal metastases. Moreover, the adverse prognosis associated with c-erbB-2 overexpression in node-positive patients was observed whether or not the patients had received adjuvant chemotherapy.
Similar content being viewed by others
References
The National Board of Health and Welfare, Centre for Epidemiology: Cancer incidence in Sweden 1995, Stockholm, 1998
Walker RA, Lees E, Webb MB, Dearing SJ: Breast carcinomas in young women (<35 years) are different. Br J Cancer 74: 1796-1800, 1996
de la Rochefordière A, Asselain B, Campana F, Scholl S, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A: Age as a prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039-1043, 1993
Chung M, Chang HR, Bland KI, Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77: 97-103, 1996
Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12: 888-894, 1994
Høst H, Lund E: Age as a prognostic factor in breast cancer. Cancer 57: 2217-2221, 1986
Adami HO, Malker B, Holmberg L, Persson I, Stone B: The relationship between survival and age at diagnosis in breast cancer. N Engl J Med 315: 559-563, 1986
Bonnier P, Romain P, Charpin C, Lejeune C, Tubiana N, Martin PM, Piana L: Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. Int J Cancer 62: 138-144, 1995
Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994
Révillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998
Borg Å, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, Killander D, McGuire WL: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50: 4332-4337, 1990
O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between cerbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444-446, 1991
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderbergh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J and Senn HJ for the International (Ludwig) Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992
Stål O, Sullivan S, Sun X-F, Wingren S, Nordenskjöld B: Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16: 160-168, 1994
Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jäger W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43: 87-95, 1997
Stål O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjöld B: C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 2185-2190, 1995
Stål O, Klintenberg C, Sullivan S and the Southeast Sweden Breast Cancer Group: Overexpression of c-erbB-2 protein and locoregional recurrence in node-positive breast cancer. The Breast 6: 354-360, 1997
Xing WR, Gilchrist KW, Harris CP, Samson W, Meisner LF: FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 39: 203-212, 1996
Bertheau P, Steinberg SM, Merino MJ: C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 29: 323-329, 1998
Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud T, van de Vijver MJ: P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16: 470-479, 1998
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell cycle regulators p27 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997
Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG: C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438, 1991
Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, Myskov M, Spedding A, Barraclough BR, Rudland PS: The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447-450, 1991
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KPH, Hartwick WR, Hanna W, Lickley L, Wilkinson R, Quizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W and McCready D for the Toronto Breast Cancer Study Group: Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16: 1340-1349, 1998
Quénel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM: The prognostic value of cerbB2 in primary breast carcinomas: A study on 942 cases. Breast Cancer Res Treat 35: 283-291, 1995
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992
Schimmelpenning H, Eriksson ET, Falkmer UG, Rutqvist LE, Johansson H, Fallenius A, Auer GU: Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. Eur J Surg Oncol 19: 530-537, 1992
Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, Gullick WJ, Elston CW, Blamey RW: C-erbB-2 C-erbB-2 in early onset breast cancer 29 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439-443, 1991
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
Paik S, Bryant J, Park C, Fisher B, Tan-chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Agrup, M., Stäl, O., Olsen, K. et al. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 63, 23–29 (2000). https://doi.org/10.1023/A:1006498721508
Issue Date:
DOI: https://doi.org/10.1023/A:1006498721508